WO2004078163A2 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen - Google Patents

Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Download PDF

Info

Publication number
WO2004078163A2
WO2004078163A2 PCT/US2004/006288 US2004006288W WO2004078163A2 WO 2004078163 A2 WO2004078163 A2 WO 2004078163A2 US 2004006288 W US2004006288 W US 2004006288W WO 2004078163 A2 WO2004078163 A2 WO 2004078163A2
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
acid
degrees
ray diffraction
diffraction pattern
Prior art date
Application number
PCT/US2004/006288
Other languages
French (fr)
Other versions
WO2004078163A3 (en
Inventor
Örn ALMARSSON
Magali Bourghol Hickey
Matthew Peterson
Michael J. Zaworotko
Brian Moulton
Nair Rodriguez-Hornedo
Original Assignee
Transform Pharmaceuticals, Inc.
University Of South Florida
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US45121303P priority Critical
Priority to US60/451,213 priority
Priority to USPCT/US03/06662 priority
Priority to PCT/US2003/006662 priority patent/WO2003074474A2/en
Priority to US60/456,027 priority
Priority to US45602703P priority
Priority to US46396203P priority
Priority to US60/463,962 priority
Priority to US10/449,307 priority
Priority to US10/449,307 priority patent/US7078526B2/en
Priority to PCT/US2003/019574 priority patent/WO2004000284A1/en
Priority to US10/601,092 priority
Priority to USPCT/US03/19574 priority
Priority to US10/601,092 priority patent/US20050025791A1/en
Priority to US60/487,064 priority
Priority to US48706403P priority
Priority to PCT/US2003/027772 priority patent/WO2004078161A1/en
Priority to USPCT/US03/27772 priority
Priority to US10/660,202 priority
Priority to US10/660,202 priority patent/US7927613B2/en
Priority to US60/508,208 priority
Priority to US50820803P priority
Priority to USPCT/US03/41273 priority
Priority to PCT/US2003/041273 priority patent/WO2004061433A1/en
Priority to US60/542,752 priority
Priority to US54275204P priority
Priority claimed from US10/546,963 external-priority patent/US20070059356A1/en
Application filed by Transform Pharmaceuticals, Inc., University Of South Florida, The Regents Of The University Of Michigan filed Critical Transform Pharmaceuticals, Inc.
Priority claimed from US10/551,014 external-priority patent/US20060223794A1/en
Priority claimed from PCT/US2004/009947 external-priority patent/WO2004089313A2/en
Priority claimed from US10/926,842 external-priority patent/US7446107B2/en
Priority claimed from EP04782868A external-priority patent/EP1718640A4/en
Priority claimed from EP20040783308 external-priority patent/EP1670753A4/en
Publication of WO2004078163A2 publication Critical patent/WO2004078163A2/en
Publication of WO2004078163A3 publication Critical patent/WO2004078163A3/en
Priority claimed from US12/234,420 external-priority patent/US20090088443A1/en
Priority claimed from US12/792,415 external-priority patent/US20100311701A1/en

Links